Figure 3.

Scatter plots of data showing % PARP enzyme inhibition levels relative to pretreatment levels (black circles) in patients' PBLs following treatment with rucaparib. (A) All dose levels at ∼24 h following last dose of rucaparib except for the twice daily schedules when levels were taken ∼12 h after last dose. Data for the 92 mg o.d. cohorts only are shown in (B) 7 days continuous dosing, (C) 14 days continuous dosing and (D) 21 days continuous dosing. The line represents the mean % inhibition.